PepGen

PEPGEN INC

PepGen Inc is a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapeutics to transform the treatment of severe neuromuscular and neurologic diseases. The company has developed its Enhanced Delivery Oligonucleotide platform to improve the uptake and activity of conjugated oligonucleotide therapeutics. Its EDO peptides are engineered to optimize tissue penetration, cellular uptake, and nuclear delivery, and in preclinical studies, it is observed their ability to transport oligonucleotides into a broad range of target tissues, including smooth, skeletal, and cardiac muscle and the central nervous system. Its pipeline products are; PGN-EDO51, PGN-EDODM1, and others including PGN-EDO53 and PGN-EDO45.

Medicine,Development,Laboratory:,Caucasian,Female,Scientist,Using,Microscope,,Analyzes,Petri

Biotech

News

Health Care

Movers

Trading Ideas

General

PEPG

PepGen halts its Phase 2 CONNECT2 trial for PGN-EDO51 in DMD to assess 10 mg/kg cohort data, while advancing FREEDOM-DM1 studies in myotonic dystrophy.

PepGen To Voluntarily Pause Mid-Stage Duchenne Muscular Dystrophy Study, Stock Falls

vaccine-4892059

PepGen shares are trading higher by 90% during Monday&#39;s session. The company announced early data from its FREEDOM-DM1 trial for myotonic dystrophy.

Why PepGen (PEPG) Stock Is Skyrocketing Today

Roku.Shutterstock

Price Target

Pre-Market Outlook

Markets

Analyst Ratings

ADSK

BELFB

COIN

PLUG

ROKU

SNDX

Roku To Rally Around 31%? Here Are 10 Top Analyst Forecasts For Monday

PepGen Inc

Legal

Press Releases

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PepGen Inc - PEPG

PepGen Announces Appointment of Two New Directors to its Board

PepGen to Present at the 24th Annual Needham Virtual Healthcare Conference

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PepGen Inc. - PEPG

PepGen Reports First Quarter 2025 Financial Results and Recent Corporate Highlights

PepGen Appoints Kasra Kasraian, PhD, as Chief Technology Officer

Adverum Biotechnologies, Inc. - Common Stock

Adverum Biotechnologies

Annovis Bio

Artiva Biotherapeutics, Inc. - Common Stock

Artiva Biotherapeutics

Atara Biotherapeutics, Inc. - Common Stock

Atara Biotherapeutics

Avalo Therapeutics

bluebird bio

Connect Biopharma Holdings Limited - American Depositary Shares

Connect Biopharma Hldgs

Precision BioSciences, Inc. - Common Stock

Precision BioSciences

Fortress Biotech

Forte Biosciences

Werewolf Therapeutics, Inc. - Common Stock

Werewolf Therapeutics

Immuneering Corporation - Class A Common Stock

Immuneering

Century Therapeutics, Inc. - Common Stock

Century Therapeutics

Kronos Bio

Mersana Therapeutics, Inc. - Common Stock

Mersana Therapeutics

Mural Oncology

OS Therapies

PMV Pharma

Prelude Therapeutics Incorporated - Common Stock

Prelude Therapeutics

Quince Therapeutics

Rein Therapeutics

RenovoRx

Shattuck Labs

vTv Therapeutics Inc. - Class A Common Stock

vTv Therapeutics

Xilio Therapeutics

HC Wainwright & Co.

B of A Securities

Wedbush

Stifel

SVB Leerink

Comments

PepGen

Connect With Us

About Benzinga

Market Resources

Trading Tools & Education

Ring the Bell